Balance Sheet Insights: Arbutus Biopharma Corp (ABUS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

In the latest session, Arbutus Biopharma Corp (NASDAQ: ABUS) closed at $3.14 down -1.87% from its previous closing price of $3.20. In other words, the price has decreased by -$1.87 from its previous closing price. On the day, 1.17 million shares were traded. ABUS stock price reached its highest trading level at $3.21 during the session, while it also had its lowest trading level at $3.11.


For a deeper understanding of Arbutus Biopharma Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.69 and its Current Ratio is at 6.69. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.

On February 25, 2021, Jefferies started tracking the stock assigning a Hold rating and target price of $5.

On December 17, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on December 17, 2020, with a $10 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 02 ’24 when McElhaugh Michael J. sold 10,164 shares for $2.31 per share. The transaction valued at 23,504 led to the insider holds 1,504,793 shares of the business.

Sofia Michael J. sold 9,982 shares of ABUS for $23,083 on Feb 02 ’24. The Chief Scientific Officer now owns 1,485,121 shares after completing the transaction at $2.31 per share. On Feb 02 ’24, another insider, HASTINGS DAVID C, who serves as the Chief Financial Officer of the company, sold 9,593 shares for $2.31 each. As a result, the insider received 22,184 and left with 181,907 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABUS now has a Market Capitalization of 592571392 and an Enterprise Value of 471411680. For the stock, the TTM Price-to-Sale (P/S) ratio is 45.62 while its Price-to-Book (P/B) ratio in mrq is 4.94. Its current Enterprise Value per Revenue stands at 36.302 whereas that against EBITDA is -5.994.

Stock Price History:

Over the past 52 weeks, ABUS has reached a high of $3.64, while it has fallen to a 52-week low of $1.69. The 50-Day Moving Average of the stock is 5.85%, while the 200-Day Moving Average is calculated to be 30.34%.

Shares Statistics:

For the past three months, ABUS has traded an average of 1.23M shares per day and 1246520 over the past ten days. A total of 169.87M shares are outstanding, with a floating share count of 144.66M. Insiders hold about 23.35% of the company’s shares, while institutions hold 44.02% stake in the company. Shares short for ABUS as of 1715731200 were 5336963 with a Short Ratio of 4.35, compared to 1713139200 on 5170836. Therefore, it implies a Short% of Shares Outstanding of 5336963 and a Short% of Float of 3.5900000000000003.

Most Popular